Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 69-year-old man with a history of low back pain for more than 4 months underwent Tc-MDP bone scan to determine the cause of the symptoms. In addition to the osseous lesions, significant activity in the stomach wall was noted. However, a subsequent F-NaF PET/CT only revealed bone lesion without increased activity in the stomach wall. The cause of the back pain was eventually confirmed due to multiple myeloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000001311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiple myeloma complicated with spinal infiltration: a case report.
Neurol Sci
September 2025
Department of Neurosurgery, The 940, Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, No.333 Nanbinhe Road, Qilihe District, Lanzhou City, Gansu Province, China.
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDFEarly Attrition and Excess Mortality in Multiple Myeloma: Lessons From Real-World Evidence.
Clin Lymphoma Myeloma Leuk
August 2025
HBS Medical and Dental College, Islamabad Pakistan.
Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702).
Blood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFAI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies.
Eur J Cancer
August 2025
Emory University, Atlanta, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA; Atlanta Veterans Administration Medical Center, Atlanta, USA. Electronic address:
Background: Early detection of hematological malignancies improves long-term survival but remains a critical challenge due to heterogeneity in clinical presentation. Chronic inflammation is a key driver in hematologic cancers and is known to induce compensatory microvascular changes. High-resolution, non-invasive retinal imaging can allow the quantification of microvascular changes for the early detection of hematological malignancies.
View Article and Find Full Text PDF